An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled Bosutinib in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 May 2009
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia; Polycystic kidney disease
- Focus Pharmacodynamics
- Sponsors Wyeth
- 01 May 2009 Actual initiation date changed from Nov 2008 to Dec 2008 as reported by ClinicalTrials.gov.
- 01 May 2009 Planned end date changed from 1 Nov 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.